Detection of Cells Translocated with Yersinia Yops in Infected Tissues Using β-Lactamase Fusions.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2019
Historique:
entrez: 10 6 2019
pubmed: 10 6 2019
medline: 26 3 2020
Statut: ppublish

Résumé

Development of the TEM-CCF2/4-AM FRET-based system has enabled investigators to track translocation of effector proteins into mammalian cells during infection. This allows for separation of translocated and non-translocated cell populations for further study. Yersinia strains expressing translational Yop-TEM fusions, containing the secretion and translocation signals of a Yop with the TEM-1 portion of β-lactamase, are used to infect mice, tissues isolated from mice, or mammalian cells in culture. Infected and harvested mammalian cells are treated with either CCF2-AM or CCF4-AM, and cleavage of this fluorescent compound by TEM is detected by fluorescence-activated cell sorting (FACS) analysis. A shift from green to blue emission spectra of individual cells is indicative of translocation of a given Yop-TEM fusion protein into the host cell during Yersinia infection due to a disruption in FRET between the two fluors of the compound. In Yersinia, this method has been used to understand Type III secretion dynamics and Yop functions in cells translocated by effectors during infection. Here, we describe how to generate Yop-TEM constructs, and how to detect, quantify, isolate, and study Yop-TEM containing cells in murine tissues during infection and in ex vivo tissues by cell sorting and flow cytometry analysis. In addition, we provide guidance for analyzing TEM-positive cells via a plate reader and fluorescent microscopy.

Identifiants

pubmed: 31177435
doi: 10.1007/978-1-4939-9541-7_9
pmc: PMC6733027
mid: NIHMS1049056
doi:

Substances chimiques

Bacterial Proteins 0
Recombinant Fusion Proteins 0
Type III Secretion Systems 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-139

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI107055
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI113166
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI128093
Pays : United States
Organisme : NIAID NIH HHS
ID : R41 AI122433
Pays : United States

Références

J Bacteriol. 1981 Dec;148(3):877-83
pubmed: 6273385
Proc Natl Acad Sci U S A. 1978 Aug;75(8):3737-41
pubmed: 358200
PLoS Pathog. 2010 Nov 24;6(11):e1001212
pubmed: 21124820
Cell Microbiol. 2010 Aug;12(8):1064-82
pubmed: 20148898
PLoS Pathog. 2009 Aug;5(8):e1000551
pubmed: 19680448
Antimicrob Agents Chemother. 1972 Apr;1(4):283-8
pubmed: 4208895
Science. 2005 Sep 9;309(5741):1739-41
pubmed: 16051750
Cell Microbiol. 2015 Aug;17(8):1179-204
pubmed: 25678064
Mol Microbiol. 2011 Mar;79(6):1445-61
pubmed: 21205017
ILAR J. 2012;53(1):E55-69
pubmed: 23382271
Curr Opin Microbiol. 2016 Feb;29:56-62
pubmed: 26638030
Front Cell Infect Microbiol. 2013 Feb 06;3:4
pubmed: 23390616
Mol Microbiol. 1994 Nov;14(3):583-94
pubmed: 7885236
PLoS One. 2012;7(3):e34039
pubmed: 22479512
Antimicrob Agents Chemother. 2014;58(2):1118-26
pubmed: 24295981
Cell Host Microbe. 2013 Sep 11;14(3):306-17
pubmed: 24034616
Microbiol Mol Biol Rev. 1998 Dec;62(4):1315-52
pubmed: 9841674
Infect Immun. 1980 Jun;28(3):1044-7
pubmed: 6249747
PLoS Pathog. 2013;9(10):e1003679
pubmed: 24098126
PLoS Pathog. 2013;9(6):e1003415
pubmed: 23818844
J Bacteriol. 2004 Aug;186(16):5486-95
pubmed: 15292151
Mol Microbiol. 2013 Jan;87(2):301-17
pubmed: 23205707
Antimicrob Agents Chemother. 2010 Aug;54(8):3241-54
pubmed: 20498321
Science. 1998 Jan 2;279(5347):84-8
pubmed: 9417030
PLoS Pathog. 2015 Oct 15;11(10):e1005167
pubmed: 26468944
Trends Microbiol. 2018 Apr;26(4):266-283
pubmed: 29477730
Cell Microbiol. 2014 Feb;16(2):247-68
pubmed: 24119087

Auteurs

Giang T Nguyen (GT)

Immunology Graduate Program, Sackler School of Biomedical Science, Boston, MA, USA.
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.

Anne L McCabe (AL)

Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.

Alyssa C Fasciano (AC)

Immunology Graduate Program, Sackler School of Biomedical Science, Boston, MA, USA.
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.

Joan Mecsas (J)

Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA. joan.mecsas@tufts.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH